MetaCap

BlossomHill Therapeutics (BLSM) vs Evotec (EVO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Evotec is the larger company by market cap ($469.1 million vs $461.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BLSM-9.31%EVO-34.00%
+73%+17%-39%
Aug 7, 20261 yearNov 20, 2026
BLSM-9.31%EVO-34.00%
+66%+13%-39%
Aug 3, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BLSM versus EVO key metrics
MetricBLSMEVO
Share price$14.51$1.32
Market cap$461.20M$469.11M
1-day change+0.69%-8.97%
YTD return—-57.14%
1-year return—-55.56%
5-year return—-94.44%
EPS (TTM)$-10.38$-0.59
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$27.99$3.87
52-week low$11.02$1.32
Distance from 52-week high-48.16%-65.89%
Analyst consensusstrong_buybuy
Avg. price target upside+143.97%+237.12%
Average volume193.15K109.16K
Shares outstanding31.78M355.39M
Employees694,379
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About BlossomHill Therapeutics

BLSM stock →

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

About Evotec

EVO stock →

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics.

Health Care · Biotechnology: Pharmaceutical Preparations · 4,379 employees

BLSM vs EVO FAQ

Which is bigger, BlossomHill Therapeutics or Evotec?

Evotec (EVO) is larger, with a market capitalization of $469.11M compared with $461.20M for BlossomHill Therapeutics (BLSM).

Are BlossomHill Therapeutics and Evotec in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons